A Troubling Appointment: Is Bias Creeping into Drug Regulation?
In a move that has sparked concern among FDA staff, Tracy Beth Høeg is set to take on a critical role as the acting director of the FDA's Center for Drug Evaluation and Research. But here's where it gets controversial: Høeg's past statements and actions have raised eyebrows, leaving many questioning her ability to lead this vital regulatory body.
Seventeen years ago, Høeg, then a resident physician and an avid ultramarathon runner, voiced her strong opposition to Sarah Palin's climate change denial. In a blog post, she expressed her dismay at Palin's disregard for scientific evidence, questioning the future of our planet under such leadership. Fast forward to the present, and Høeg finds herself in a similar situation, accused of the very thing she once criticized.
As the top drug regulator in the US, Høeg's nine months as a scientific adviser have left some of her colleagues and staff questioning her impartiality. The role demands an objective review of complex scientific data, yet Høeg's track record has sparked doubts about her ability to remain unbiased.
And this is the part most people miss: Høeg's appointment comes at a time when the FDA is already under scrutiny. With the Center for Drug Evaluation and Research facing numerous challenges, the need for a steady hand at the helm is crucial. So, the question arises: Can Høeg provide the stability and impartiality required to navigate these turbulent waters?
This story, exclusively for STAT+ subscribers, delves deeper into the concerns surrounding Høeg's appointment. It's a must-read for anyone interested in the future of drug regulation and the potential impact on public health. Join the discussion and share your thoughts in the comments. Is Høeg the right person for the job, or does her past raise too many red flags?
